Journal of Clinical Endocrinology & Metabolism, Vol 63, 1174-1180, Copyright © 1986 by Endocrine Society

ARTICLES

Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture

A Gompel, C Malet, P Spritzer, JP Lalardrie, F Kuttenn and P Mauvais-Jarvis

In contrast to cancer cell lines, normal human breast epithelial cells are infrequently studied. Such cells, now routinely cultured in our laboratory from tissue obtained at the time of reduction mammoplasty, were used to study the actions of estradiol (E2), the progestin promegestone (R5020), and the antiprogesterone RU486 on cell growth and progesterone-dependent 17 beta-hydroxysteroid dehydrogenase (E2DH) activity, which is considered good marker of epithelial differentiation as well as progesterone dependency. The studies were carried out using secondary cultures to assure equal initial cell distribution. Cell growth was estimated daily by a histometric method providing a growth index and DNA assay. E2 stimulation of cell growth was not found when the cells were grown in our usual culture medium, but E2 dose-dependent growth stimulation occurred in medium minimally supplemented with serum (1%), insulin; and epidermal growth factor. R5020 inhibited cell growth and stimulated E2DH activity in a dose-dependent manner. RU486 behaved as a pure but low potent progestin agonist concerning E2DH stimulation, but as an agonist with partial antagonist properties concerning cell growth inhibition. In conclusion, E2 stimulated proliferation of human breast epithelial cells in culture, whereas the progestin R5020 inhibited cell multiplication and favored differentiation. The antiprogesterone RU486 had a biphasic effect acting both as progestin agonist and partial antagonist.

This article has been cited by other articles:

				Y. Liang, C. Besch-Williford, R. A. Brekken, and S. M. Hyder Progestin-Dependent Progression of Human Breast Tumor Xenografts: A Novel Model for Evaluating Antitumor Therapeutics Cancer Res., October 15, 2007; 67(20): 9929 - 9936. [Abstract] [Full Text] [PDF]

				F. Souaze, S. Dupouy, V. Viardot-Foucault, E. Bruyneel, S. Attoub, C. Gespach, A. Gompel, and P. Forgez Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression. Cancer Res., June 15, 2006; 66(12): 6243 - 6249. [Abstract] [Full Text] [PDF]

				F. Souaze, V. Viardot-Foucault, N. Roullet, M. Toy-Miou-Leong, A. Gompel, E. Bruyneel, E. Comperat, M. C Faux, M. Mareel, W. Rostene, et al. Neurotensin receptor 1 gene activation by the Tcf/{beta}-catenin pathway is an early event in human colonic adenomas Carcinogenesis, April 1, 2006; 27(4): 708 - 716. [Abstract] [Full Text] [PDF]

				M. Wahab, A.H. Taylor, J.H. Pringle, J. Thompson, and F. Al-Azzawi Trimegestone differentially modulates the expression of matrix metalloproteinases in the endometrial stromal cell Mol. Hum. Reprod., March 1, 2006; 12(3): 157 - 167. [Abstract] [Full Text] [PDF]

				C. A. Sartorius, D. M.E. Harvell, T. Shen, and K. B. Horwitz Progestins Initiate a Luminal to Myoepithelial Switch in Estrogen-Dependent Human Breast Tumors without Altering Growth Cancer Res., November 1, 2005; 65(21): 9779 - 9788. [Abstract] [Full Text] [PDF]

				D. Levy, G. Plu-Bureau, Y. Decroix, D. Hugol, W. Rostene, A. Kimchi, and A. Gompel Death-Associated Protein Kinase Loss of Expression Is a New Marker for Breast Cancer Prognosis Clin. Cancer Res., May 1, 2004; 10(9): 3124 - 3130. [Abstract] [Full Text] [PDF]

				T. M. Ahola, T. Manninen, N. Alkio, and T. Ylikomi G Protein-Coupled Receptor 30 Is Critical for a Progestin-Induced Growth Inhibition in MCF-7 Breast Cancer Cells Endocrinology, September 1, 2002; 143(9): 3376 - 3384. [Abstract] [Full Text] [PDF]

				Z. Gao, H. Matsuo, S. Nakago, O. Kurachi, and T. Maruo p53 Tumor Suppressor Protein Content in Human Uterine Leiomyomas and Its Down-Regulation by 17{beta}-Estradiol J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3915 - 3920. [Abstract] [Full Text] [PDF]

				P. A. Newcomb, L. Titus-Ernstoff, K. M. Egan, A. Trentham-Dietz, J. A. Baron, B. E. Storer, W. C. Willett, and M. J. Stampfer Postmenopausal Estrogen and Progestin Use in Relation to Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 593 - 600. [Abstract] [Full Text] [PDF]

				J. P. Wiebe, D. Muzia, J. Hu, D. Szwajcer, S. A. Hill, and J. L. Seachrist The 4-Pregnene and 5{{alpha}}-Pregnane Progesterone Metabolites Formed in Nontumorous and Tumorous Breast Tissue Have Opposite Effects on Breast Cell Proliferation and Adhesion Cancer Res., February 1, 2000; 60(4): 936 - 943. [Abstract] [Full Text]

				J. D. Graham and C. L. Clarke Physiological Action of Progesterone in Target Tissues Endocr. Rev., August 1, 1997; 18(4): 502 - 519. [Abstract] [Full Text] [PDF]

				C. Dabrosin, K. Ollinger, U. Ungerstedt, and M. Hammar Variability of Glutathione Levels in Normal Breast Tissue and Subcutaneous Fat during the Menstrual Cycle: An in Vivo Study with Microdialysis Technique J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1382 - 1384. [Abstract] [Full Text] [PDF]